🇺🇸 FDA
Pipeline program

Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

111-208

Phase 2 small_molecule active

Quick answer

Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. for Achondroplasia is a Phase 2 program (small_molecule) at BIOMARIN PHARMACEUTICAL INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOMARIN PHARMACEUTICAL INC
Indication
Achondroplasia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials